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Abstract: The aminosalicylates (5-ASA; also referred to as mesalamine-based agents) 
are considered as first-line in the maintenance of remission of mild to moderate ulcerative 
colitis (UC). Traditionally these agents have required a large pill burden and multiple daily 
dosing regimens which may account for the low adherence rates, especially in patients in 
remission. Extended-release mesalamine is the first once daily mesalamine product approved 
by the Food and Drug Administration for the maintenance of UC remission. This review will 
examine the pharmacokinetics, dosing, efficacy, and safety data of extended-release mesalamine, 
and discuss the potential role of improving medication compliance and decreasing costs in UC 
maintenance.
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Introduction
Ulcerative colitis (UC) is a chronic relapsing–remitting inflammatory condition that 
affects up to 238 per 100,000 persons in North America.1 The goals of treatment of 
UC include achieving and maintaining symptom-free remission with minimal side-
effects. The aminosalicylates (5-ASA; also referred to as mesalamine-based agents) 
are the recommended first-line therapy for induction and maintenance of remission 
in mild to moderate UC.2 The mechanism of action of these agents is unknown but 
there is evidence to show that they have many direct anti-inflammatory effects on the 
colonic mucosa. One of the major mechanisms appears to be mediated by local inhibi-
tion of the activation of nuclear factor-κB, which is a central transcription regulatory 
factor involved in initiating and perpetuating inflammatory processes.3,4 These local 
anti-inflammatory effects are dependent on the ability of the active drug to reach 
the site of inflammation intact; therefore different 5-ASA formulations have been 
designed to ensure the drug is not degraded or absorbed before reaching the inflamed 
mucosa. These formulations include pH-dependent enteric coatings that release the 
active drug at a set pH, pro-drug formulations that depend on colonic bacteria for drug 
release, and moisture-dependent coatings that facilitate delayed release of mesalamine. 
Traditionally, 5-ASA formulations have required multiple daily dosing and a large 
pill burden, which may account for their low adherence rates of only 40% to 60%,5,6 
especially challenging in patients who are in remission.7–10 Lack of adherence to 
5-ASA agents has been shown to increase the probability of clinical relapse in UC11 
and has been related to increased costs of disease.12–14 As a result, there has been much 
interest in the development of effective, once daily-dosed mesalamine products, with Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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the expectation of greater compliance, and decreased disease 
burden and costs.
Extended-release mesalamine (Apriso™;  Salix 
Pharmaceuticals, Morrisville, NC) is the first once daily-
dosed mesalamine product indicated for the maintenance of 
UC remission released in the United States. This granulated 
mesalamine formulation is available elsewhere in the world 
under the trade name Salofalk® (Dr Falk Pharma GmbH, 
Freiburg, Germany), with data for induction of UC. This 
review will examine the pharmacokinetics, dosing, efficacy, 
and safety data of extended-release mesalamine, and discuss 
the potential role of improving medication compliance in 
UC maintenance.
Pharmacokinetics
Background
The therapeutic efficacy of 5-ASA agents in the treatment 
of UC depends on the ability of the mesalamine to reach the 
mucosal surface of the inflamed colon; systemic absorption 
is not known to have additional benefit and is generally 
considered undesirable due to concerns of mesalamine-
induced nephrotoxicity. Since mesalamine would be rapidly 
absorbed from the small intestine if left unprotected, the 
challenge has been to transfer mesalamine unadulterated 
through the upper and middle intestinal tract, but then have 
effective release in the lower tract to allow luminal contact 
between the active 5-ASA and the colonic mucosa.
Some of the 5-ASA formulations use pH-dependent 
mechanisms to ensure delivery to the site of action. The two 
most commonly used pH-dependent delivery systems 
utilize a Eudragit®-S resin (designed to dissolve at pH $ 7), 
and a Eudragit®-L resin (Evonik Rohm GmbH, Darmstadt, 
Germany), which disintegrates at pH $ 6. Variability in pH 
throughout the gut can therefore have a marked effect on 
the location of the release of mesalamine that is coated or 
otherwise protected by these agents.
Studies of gut luminal pH levels  
and colonic transit time
The pH throughout the gut of both healthy volunteers and 
patients with mild to moderate UC has been measured and 
compared in small studies. Using 13 healthy volunteers, 
Fallingborg et al15 determined the pH in the stomach to 
be ,3.0 in all patients. Median pH was 6.6 in the proxi-
mal small bowel, 7.3 in the distal small bowel, 5.7 in the 
right colon, and 6.6 in the left colon. In 10 patients with 
mild to moderate UC, the results were similar. Rubin et al 
used the newly developed SmartPill pHp™ (the SmartPill 
Corporation, Buffalo, NY) to study 10 patients with active 
UC: 9 were male, 4 with pancolitis, 6 with left-sided colitis.16 
Mean pH levels are shown in Figure 1. All 10 patients 
achieved a luminal pH of $6.0 for a minimum of 120 min-
utes; 1 patient never reached a pH of 7.0, and 6 patients 
maintained pH $ 7.0 for less than 120 minutes.
Bosworth et al17 compared the pH and transit times 
between 5 otherwise healthy UC patients and 5 normal 
controls. There was no difference in the mean pH of the 
small bowel (mean ± SD: 6.89 ± 0.72 in the UC patients vs 
6.83 ± 0.01 in the controls) between the two groups but the 
mean colonic pH in the UC patients was significantly lower 
than that of the normal controls (mean ± SD: 6.14 ± 0.37 
vs 7.06 ± 0.41, P = 0.006). The number of hours that 
a pH of .7.0 or .6.0 was achieved in the colon was 
significantly less in the UC patients as compared to the 
controls (mean ± SD: 4.33 ± 2.32 hours vs 14.10 ± 6.31 hours, 
P = 0.01, for pH . 6.0; 0.30 ± 0.17 hours vs 9.33 ± 5.29 hours, 
P = 0.005, for pH . 7.0, respectively).
The implications of a more acidic colonic luminal pH 
in patients with active UC could include the modification 
of the most desirable pH release system for the delivery of 
a luminally active medication, such as mesalamine. The pH 
levels of a UC colon in remission have not been well studied 
but would be presumably less acidic that in active colitis.
Some of these same studies also measured colonic 
transit times.15–17 In normal volunteers the median colonic 
transit time was 17.5 hours15 and in patients with mild to 
moderate UC the mean colonic transit time was 15.41 hours 
(range 6.91–23.91).16 When mild UC patients were compared 
with normal controls, there was no significant difference 
in mean colonic transit time between the two groups 
(mean ± SD: 12.66 ± 5.37 vs 30.68 ± 21.47, P = 0.10).17
Stomach: 1.94
Proximal small bowel: 5.82
Distal small bowel: 7.08
Right colon: 6.01
Left colon: 6.52
Figure 1 Mean luminal pH measurement in 10 patients with active ulcerative colitis.16Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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extended-release mesalamine
Extended-release mesalamine consists of a gelatin capsule 
filled with hundreds of tiny mesalamine granules, each of 
which is encapsulated in an outer Eudragit®-L coating that is 
intended to protect the mesalamine from degradation in the 
stomach and begin breaking down at pH $ 6. The intestinal 
contents then activate an inner core of the mesalamine 
granules, which is made of a polymer matrix that allows for 
time-dependent release of mesalamine.18 Pharmacokinetic 
studies have shown that this mesalamine formulation 
arrives in the small intestine after 0.8 ± 0.5 (mean ± SD) 
hours and in the ileum after 4 ± 1 hours.19 The tablets start 
to disintegrate when they reach the colon after a mean of 
5.8 ± 1.2 hours post-dose and the initial disintegration of 
the tablets start in the ascending or transverse colon after an 
average of 6.9 ± 1.1 hours post-dose. The tablets arrive in 
the transverse colon after a mean of 7.3 ± 1 hours and in the 
descending colon after a mean of 9.5 ± 2.1 hours.19,20
An estimated 32% ± 11% (mean ± SD) of the administered 
dose of extended-release mesalamine is absorbed systemi-
cally in the fasting state and peak plasma concentrations are 
observed at about 4 hours after administration.18
The pharmacokinetics, safety, and tolerability of once 
daily versus twice daily dosing of 1.6 g of extended-release 
mesalamine in 30 healthy volunteers showed that both dosing 
regimens were comparable in terms of systemic exposure 
(area under the curve, AUC), although the time to maximum 
concentration was shorter in the once daily group versus the 
twice daily group.21 Adverse events did not differ between 
the two groups. The effect of a high-fat meal on the phar-
macokinetics of 1.6 g mesalamine granules in 30 healthy 
volunteers was also analyzed, with no difference shown in the 
maximum plasma concentration (Cmax) or the AUC between 
the fasting and high-fat states, although the time to Cmax was 
increased by a high-fat meal.22 Based on these results, the 
once daily extended-release granulated mesalamine may be 
dosed with or without food.
Dosing
The current Food and Drug Administration (FDA) 
approved dose for granulated extended-release mesalamine 
for maintenance of UC remission is 1.5 g (four 0.375 g 
capsules) once daily in the morning. Other doses have 
been tested in the induction and in the maintenance of 
remission of UC.
One randomized double-blind, dose-finding induction 
study compared 3 different daily doses of granulated 
extended-release mesalamine (1.5 g, 3.0 g, and 4.5 g) for 
8 weeks in 321 patients with mild to moderate active UC.23 
Clinical remission was measured by the Rachmilewitz 
clinical activity index (CAI; number of stools, percentage 
of bloody stools, abdominal pain, general well-being, fever, 
extraintestinal manifestations, erythrocyte sedimentation rate, 
and hemoglobin). Rates of clinical remission are shown in 
Figure 2. Endoscopic response rates, measured by a 5-point 
index assessing granularity, vascular pattern, vulnerability, 
and integrity of the mucosa, were 53% (1.5 g), 84% (3.0 g), 
and 70% (4.5 g), with significant differences seen between 
the 1.5 g and 3.0 g groups. Histological improvement rates 
were 42%, 63%, and 56%, respectively, as determined by the 
4-point Riley score. Global tolerability was found to be very 
good or good in 82% of patients in the 1.5 g group, 88% in 
the 3.0 g/day group and 75% in the 4.5 g group.
A different study of maintenance of UC remission 
randomized 647 patients with quiescent UC to receive 
granulated extended-release mesalamine 3.0 g once daily, 
1.5 g once daily, or 0.5 g 3 times daily for a 1 year.24 
Remission was defined as an endoscopic score of #3 within 
3 months of baseline evaluation, and as a CAI # 4. One-year 
remission rates were statistically similar at 75% (3.0 g/d), 
61% (1.5 g/d), and 70% (0.5 g 3 times daily). All three dosing 
regimens were well tolerated; there were no medication-
related serious adverse events reported.
Efficacy and safety in the maintenance  
of remission
Two randomized double-blind phase III studies compared 
the efficacy of granulated extended-release mesalamine 
(1.5 g once daily) with placebo in UC patients who were in 
remission for 1 to 12 months.25,26 Remission was defined, 
using the revised Sutherland Disease Activity Index (DAI) 
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Figure  2  Clinical  remission  rates  at  8  weeks  in  321  patients  with  active 
mild-to-moderate  ulcerative  colitis  to  three  different  daily  doses  of  granulated 
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scale, as a score of 0 on the rectal bleeding component and 
#1 on the mucosal appearance component.
The first study randomized 305 patients with quiescent 
UC; 193 (63%) completed the study.25 A total of 112 patients 
(37%) withdrew from the study due to adverse events 
(54 patients) or lack of efficacy (36 patients). The primary 
efficacy end-point, defined as the proportion of patients who 
were relapse-free after 6 months of treatment, was achieved in 
a significantly higher number of mesalamine-treated patients 
(79% vs 58% for placebo, P , 0.001). Relapse risk over the 
6-month course of the study was lower in the mesalamine 
group compared to placebo (hazard ratio = 0.42, P , 0.001). 
The adverse event rates were similar between the two groups, 
UC flares being twice as common in the placebo group than in 
the mesalamine group (27% vs 11%, respectively) and head-
aches being more common in the mesalamine group (11% vs 
7%). Two serious adverse events were reported in each group 
but only 1 (placebo group), in which a patient experienced a 
severe UC recurrence, was considered study-drug related.
The second study showed very similar results. Of 257 
patients with quiescent UC who were randomized, 176 (69%) 
completed the study.26 A total of 81 patients (32%) withdrew 
from the study due to adverse events (15 patients) or lack 
of efficacy (47 patients). The primary efficacy end-point, 
defined as the proportion of patients who were relapse-free 
after 6 months of treatment, was achieved in a significantly 
higher number of granulated extended-release mesalamine 
patients (80% vs 57% placebo, P = 0.03). Relapse risk over 
the 6-month course of the study was also lower in the mesala-
mine group compared with placebo (hazard ratio = 0.057, 
P = 0.02). The adverse event rates were similar between 
the two groups, UC flares being twice as common in the 
placebo group than in the mesalamine group (22% vs 11%, 
respectively) and headaches being more common in the 
mesalamine group (11% vs 8%). A total of five serious 
adverse events were reported in four patients (two patients 
per group) but none was considered to be related to the 
study drug.
A third placebo-controlled randomized study evaluated 
the efficacy of granulated extended-release mesalamine in the 
maintenance of remission in patients with quiescent UC who 
switched from other 5-ASA preparations.27 A total of 487 UC 
patients in remission were randomized to 1.5 g of granulated 
extended-release mesalamine once daily (N = 322) or placebo 
(N = 165) for 6 months. The 5-ASA preparations previously 
used by these patients included nongranulated mesalamine, 
sulfasalazine, balsalazide, suppositories/enemas, and 
olsalazine. Remission was defined using the revised 
Sutherland DAI scale as a score of 0 on the rectal bleeding 
component and ,2 on the mucosal appearance component. 
The primary efficacy end-point, defined as the proportion of 
patients who were relapse-free during 6 months of treatment, 
was higher in the granulated extended-release mesalamine 
group (78%) than in the placebo group (59%; P , 0.001).
Compliance issues
The efficacy of the 5-ASA agents in maintaining remission 
depends to some extent on medication adherence. 
Noncompliance rates in UC have been shown to be high, 
especially in patients with quiescent UC. Multiple studies 
have examined the reasons behind the high rates of 
noncompliance in these patients. One study investigated 
the adherence rates and risk factors for nonadherence in 94 
patients with quiescent UC and found the overall adherence 
rate to be only 40%.8 Risk factors for nonadherence included 
male gender, single marital status, and left-sided UC disease 
location. The most common reasons cited by the patients 
for their nonadherence were forgetfulness and high pill 
burden. Another separate study showed that patients with 
inactive disease were less likely to be compliant with their 
medications than symptomatic patients,9 and the high 
number of pills and multiple daily dosing were also associ-
ated with nonadherence. Other studies have reported similar 
findings.28,29
The barriers to patient compliance are important to 
understand because the consequences of nonadherence 
include increased relapse rates, which in turn impact 
morbidity, quality of life, and overall health care costs. In a 
prospective study, Kane et al11 found that nonadherence with 
mesalamine increases the risk of clinical relapse among 
patients with quiescent UC. Adherence to medication in this 
study was associated with an 89% chance of maintaining 
remission compared with only a 39% chance in patients 
who were nonadherent (P = 0.001). Overall, nonadherent 
patients had a five-fold higher risk of relapse than adherent 
patients (hazard ratio = 5.5; 95% confidence interval: 
2.3–13.0; P , 0.001).
Other potential benefits of higher levels of adherence 
with 5-ASA medications include improved patient quality 
of life and lower incidence rates of colorectal dysplasia and 
cancer. UC relapses have also been shown to have a negative 
impact on quality of life. Han et al30 studied 111 patients 
with UC and found a strong association between patients’ 
UC symptoms and quality of life. Avoidance of relapse by 
improved adherence with effective medication may help 
maintain acceptable quality of life. The long-term use of Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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5-ASA agents has been shown to possibly reduce colorectal 
cancer risk.31 This benefit is thought to be related to decreased 
inflammation secondary to decreased long-term relapse 
rates, or perhaps from COX-2 inhibition of colonic neopla-
sia. As a result, nonadherence to therapy may also lead to 
increased rates of colorectal cancer and dysplasia.
Nonadherence to medications have also been shown to 
lead to higher medical costs, due to increased rates of disease 
relapse. The average cost of a single case of treatment failure 
has been shown to exceed US$11,500 per patient.32 Compared 
to patients in remission, UC patients who relapse incur 2 to 
3 times higher costs, with a 20-fold increase in costs if the 
relapses result in a hospitalization.13 The relationship between 
health care costs and 5-ASA adherence rates in patients with 
active UC was directly studied by Mitra et al33 in 1693 UC 
patients captured in a large health insurance claims database. 
Nonadherence, defined as a 5-ASA medication possession 
ratio of ,0.8, was found in 72% of the patients; these patients 
had higher average per-patient 1-year health care costs 
(US$15,177) than patients who were adherent (US$11,331). 
Excluding pharmacy costs even further emphasized the dif-
ference, with nonadherent patients racking up average costs 
of US$12,383 versus only US$6,881 for patients who were 
adherent with their 5-ASA medications (Figure 3).
Conclusion
Traditionally, 5-ASA formulations have required multiple 
daily dosing and a large pill burden, which may account 
for their low adherence rates, especially in patients who 
are in remission. Lack of adherence to 5-ASA agents has 
been shown to increase the probability of clinical relapse 
in UC and has been related to increased costs of disease. 
Extended-release mesalamine is the first once daily-dosed 
mesalamine product FDA-indicated for the maintenance of 
UC remission. The efficacy of this formulation, simplified 
dosing regimen, and low pill burden may improve adherence 
and, as a result, decrease the frequency of relapses, lower 
the incidence of UC complications such as colon cancer, and 
reduce UC-related health care costs.
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